Bridgewater Township, New Jersey

Salix Announces 2021 Gastrointestinal Health Scholars Program Winners

Retrieved on: 
Thursday, July 22, 2021

LAVAL, Quebec, July 22, 2021 /PRNewswire/ --Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, todayannounced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.

Key Points: 
  • LAVAL, Quebec, July 22, 2021 /PRNewswire/ --Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal (GI) diseases, todayannounced the winners of its 2021 Salix Gastrointestinal Health Scholars Program.
  • The 2021 Salix Gastrointestinal Health Scholars Program recipients are:
    "I'm so grateful to receive this scholarship as I pursue my higher education in nursing school," said Madeleine Huwe, a recipient of the Undergraduate Scholar's Award.
  • To learn more about the Salix Gastrointestinal Health Scholars Program visit www.salix.com/scholarship .
  • The 2022 Salix Gastrointestinal Health Scholars Award will begin accepting applications in early 2022.

Amneal Receives Approval for Generic TobraDex®

Retrieved on: 
Monday, July 19, 2021

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex, which adds another complex ophthalmic product to the generics portfolio.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (Amneal or the Company) today announced that it has received Abbreviated New Drug Application (ANDA) approval from the U.S. Food and Drug Administration (FDA) for the generic version of TobraDex, which adds another complex ophthalmic product to the generics portfolio.
  • Dexamethasone and Tobramycin Ophthalmic Suspension 0.3%/0.1% is the generic version of TobraDex, which is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.
  • Todays announcement of an additional ophthalmic product approval in our generic portfolio is important.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.

Amneal to Report Second Quarter 2021 Results on August 9, 2021

Retrieved on: 
Thursday, July 15, 2021

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to market open.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its second quarter 2021 financial results on Monday, August 9, 2021, prior to market open.
  • The Company will host a conference call and live webcast with the investment community at 8:00 a.m. Eastern Time on August 9, 2021.
  • To access the call through a conference line, dial (844) 746-0741 (in the U.S.) or (412) 317-5273 (international callers).
  • A replay of the conference call will be posted shortly after the call and will be available for seven days.

Amneal to Virtually Participate at Upcoming Investor Conferences

Retrieved on: 
Friday, May 14, 2021

b"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that its management team will virtually attend the following investor conferences:\nFireside Chat \xe2\x80\x93 1:55 p.m. Eastern Time\nFireside Chat \xe2\x80\x93 3:50 p.m. Eastern Time\nA live webcast of the presentations will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com .

Key Points: 
  • b"Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (the \xe2\x80\x9cCompany\xe2\x80\x9d) today announced that its management team will virtually attend the following investor conferences:\nFireside Chat \xe2\x80\x93 1:55 p.m. Eastern Time\nFireside Chat \xe2\x80\x93 3:50 p.m. Eastern Time\nA live webcast of the presentations will be accessible through the Investor Relations section of the Company's website at https://investors.amneal.com .
  • The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.\nThe Company also owns 65% of AvKARE.
  • AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs.
  • For more information, visit www.amneal.com .\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210514005301/en/\n"

Epstein Ostrove, LLC named official Suite Level sponsor of the New York Yankees Double-A affiliate minor league team, the Somerset Patriots

Retrieved on: 
Friday, May 14, 2021

"The New York Yankees\' affiliation with New Jersey\'s very own Somerset Patriots represents the future of baseball.

Key Points: 
  • "The New York Yankees\' affiliation with New Jersey\'s very own Somerset Patriots represents the future of baseball.
  • Like the team here at Epstein Ostrove, these organizations achieve excellence both on and off the field.
  • We believe the Patriot\'s affiliation with the New York Yankees is a strong draw for locals as well as visitors to Somerset, who will support the growth of our community and local businesses."
  • The team\'s next home game is set for Tuesday, May 25th against the New Hampshire Fisher Cats.\nThe lawyers ofEPSTEINOSTROVE, LLC are all litigators and trial lawyers.

Acerus Reports First Quarter 2021 Financial Results

Retrieved on: 
Thursday, May 13, 2021

b'TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (\xe2\x80\x9cAcerus\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2021.

Key Points: 
  • b'TORONTO, May 13, 2021 (GLOBE NEWSWIRE) -- Acerus Pharmaceuticals Corporation (\xe2\x80\x9cAcerus\xe2\x80\x9d or the \xe2\x80\x9cCompany\xe2\x80\x9d) (TSX: ASP; OTCQB: ASPCF) today reported its financial results for the three-month period ended March 31, 2021.
  • Just as importantly, after the end of the quarter, our deal with Amneal paves the way for Acerus to more rapidly reach Endocrinology professionals in the U.S., opening up new avenues for customer interaction and acceptance.
  • The Company currently expects first orders under his agreement in the second quarter, with deliveries in the fourth quarter of 2021 and early 2022.\nThe Company also remains optimistic about a return of NATESTO\xc2\xae to Canada during 2021.
  • We use Adjusted EBITDA as a key metric in assessing our business performance when we compare results to budgets, forecasts and prior years.

Acerus Pharmaceuticals Announces Co-Promotion Agreement with Amneal Pharmaceuticals for NATESTO®

Retrieved on: 
Monday, May 10, 2021

Amneal will promote NATESTO through its 50+ sales representatives in a P2 position.\nUnder the terms of the agreement, Amneal will sell NATESTO to the company\xe2\x80\x99s existing Endocrinology targets through June 30, 2024.

Key Points: 
  • Amneal will promote NATESTO through its 50+ sales representatives in a P2 position.\nUnder the terms of the agreement, Amneal will sell NATESTO to the company\xe2\x80\x99s existing Endocrinology targets through June 30, 2024.
  • \xe2\x80\x9cThe partnership will allow our Specialty Sales Representatives to expand their reach in the Urology segment while adding high-prescribing PCPs across their covered geographies.
  • These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect.
  • You should not place undue importance on forward-looking information and should not rely upon this information as of any other date.

Amneal to Report First Quarter 2021 Results on May 7, 2021

Retrieved on: 
Thursday, April 15, 2021

b'Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open.

Key Points: 
  • b'Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced today that the Company will release its first quarter 2021 financial results on Friday, May 7, 2021, prior to market open.
  • To access the replay, dial (877) 344-7529 (in the U.S.) or (412) 317-0088 (international callers).
  • The Company also markets a portfolio of branded pharmaceutical products through its Specialty segment focused principally on central nervous system and endocrine disorders.\nThe Company also owns 65% of AvKARE.
  • AvKARE provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, primarily focused on serving the Department of Defense and the Department of Veterans Affairs.

Amneal Completes Acquisition of Kashiv Specialty Pharmaceuticals

Retrieved on: 
Monday, April 5, 2021

Amneal Pharmaceuticals, Inc. (the Company) (NYSE: AMRX) and Kashiv BioSciences LLC (Kashiv) today announced that Amneal Pharmaceuticals LLC (Amneal), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (Kashiv Specialty), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.

Key Points: 
  • Amneal Pharmaceuticals, Inc. (the Company) (NYSE: AMRX) and Kashiv BioSciences LLC (Kashiv) today announced that Amneal Pharmaceuticals LLC (Amneal), a subsidiary of the Company, has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, LLC (Kashiv Specialty), a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.
  • Through the acquisition of Kashiv Specialty Pharma, Amneal has gained an exciting pipeline of both 505(b)2 branded products and complex generics.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products.
  • Founded in 2011, Kashiv is a premier fully integrated specialty biopharmaceutical company offering next-generation drug delivery technologies and an advanced pipeline of oral & biosimilar drugs.

Amneal to Virtually Participate at Upcoming Investor Conferences

Retrieved on: 
Monday, February 22, 2021

A replay of the webcast will be posted shortly after the call and will be available for a limited time following the event.

Key Points: 
  • A replay of the webcast will be posted shortly after the call and will be available for a limited time following the event.
  • Amneal Pharmaceuticals, Inc. (NYSE: AMRX), headquartered in Bridgewater, NJ, is a fully-integrated pharmaceutical company focused on the development, manufacturing and distribution of generic and specialty drug products.
  • The Company has operations in North America, Asia, and Europe, working together to bring high-quality medicines to patients primarily within the United States.
  • Amneal has an extensive portfolio of approximately 250 product families and is expanding its portfolio to include complex dosage forms, including biosimilars, in a broad range of therapeutic areas.